Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ACH-0145228: Powder-in-capsule, ACH-0145228
ACH-0145228:in · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: ACH-0145228, Midazolam, and Digoxin | EXPERIMENTAL | Period 1: Participants received single doses of midazolam and digoxin. Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin. Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2. |
| Part 2: ACH-0145228 and Itraconazole | EXPERIMENTAL | Period 1: Participants received a single dose of ACH-0145228. Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228. Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2. |
| Name | Type | Description |
|---|---|---|
| ACH-0145228 | DRUG | ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules. |
| Midazolam | DRUG | Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup). |
| Digoxin | DRUG | Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet. |
| Itraconazole | DRUG | Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution). |
Inclusion Criteria: 1. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive, with a minimum body weight of 50.0 kg at screening. 2. No clinically significant history or presence of electrocardiogram abnormalities at screening and prior to first dosing in Period 1. 3....
ACH-0145228 is an investigational small molecule developed by AstraZeneca PLC. It is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed. A powder-in-capsule formulation has also been referenced. The compound has been studied in a single completed Phase 1 drug interaction trial.
ACH-0145228 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this investigational small molecule.
ACH-0145228 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
ACH-0145228 has been evaluated in one completed Phase 1 trial, NCT04709081, titled A Drug Interaction Study of ACH-0145228. The trial enrolled 38 healthy adult volunteers in the United States and used a randomized, controlled design.
Yes, ACH-0145228 Powder-in-capsule is an alternative name for ACH-0145228. Both refer to the same investigational small molecule developed by AstraZeneca PLC.